Location of Repository

JNK pathway is involved in the inhibition of inflammatory target gene expression and NF-kappaB activation by melittin

By Hye Ji Park, Hwa Jeong Lee, Myung Sook Choi, Dong Ju Son, Ho Sueb Song, Min Jong Song, Jeong Min Lee, Sang Bae Han, Youngsoo Kim and Jin Tae Hong
Topics: Research
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2442592
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles



    1. (2004). 7 cells. Biochem Pharmacol
    2. (2000). A: The ubiquitindependent proteolytic system and other potential targets for the modulation of nuclear factor-κB (NF-κB). Curr Drug Targets
    3. (2007). Aggarwal BB: Targeted deletion of MKK4 gene potentiates TNF-induced apoptosis through the down-regulation of NF-kappa B activation and NF-kappa B-regulated antiapoptotic gene products.
    4. (1999). Bacterial lipopolysaccharide activates nuclear factor-kappaB through interleukin-1 signaling mediators in cultured human dermal endothelial cells and mononuclear phagocytes.
    5. (2007). Bee venom and melittin reduce proinflammatory mediators in lipopolysaccharide-stimulated BV2 microglia. Int Immunopharmacol
    6. (2001). Bee venom injection into an acupuncture point reduces arthritis associated edema and nociceptive responses. Pain
    7. (2004). C: NF-kappaB inducing kinase activates NF-kappaB transcriptional activity independently of IkappaB kinase gamma through a p38 MAPK-dependent RelA phosphorylation pathway. Cell Signal
    8. (1973). CA: Letter: An anti-inflammatory peptide from bee venom. Nature
    9. CH: Rengyolone inhibits inducible nitric oxide synthase expression and nitric oxide production by down-regulation of NFkappaB and p38 MAP kinase activity in LPS-stimulated RAW
    10. (2002). Chatteriee pk, Caput AP, Thiemermann C: The cyclopentenone prostaglandin 15-deoxy-Delta(12,14)-prostaglandin J(2) attenuates the development of acute and chronic inflammation. Mol Pharmacol
    11. (2004). Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic.
    12. (1996). D: NF-kappaB: ten years after. Cell
    13. (2000). Delhase M: The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signalling. Semin Immunol
    14. (2005). DH: Anti-inflammatory effects of Magnolol and Honokiol are mediated through inhibition of the downstream pathway of MEKK-1 in NF-B activation signaling. Planta Med
    15. (1994). DL: Contribution of cyclooxygenase-1 and cyclooxygenase-2 to prostanoid formation by human enterocytes stimulated by calcium ionophore and inflammatory agents. Prostaglandins Other Lipid Mediat
    16. (2003). DM: Gold compound auranofin inhibits IkappaB kinase (IKK) by modifying Cys-179 of IKKbeta subunit. Exp Mol Med
    17. (1999). EF: Inhibitory effect of annexin I on synovial inflammation in rat adjuvant arthritis. Arthritis Rheum
    18. (2001). Firestein GS: Inhibitor of nuclear factor kappaB kinase beta is a key regulator of synovial inflammation. Arthritis Rheum
    19. (1999). FS: Mitogen-activated protein kinase/ERK kinase kinases 2 and 3 activate nuclear factor-κB through IκB kinase-α and IκB kinase-β.
    20. (2006). GY: Key regulators in bee venom-induced apoptosis are Bcl2 and caspase-3 in human leukemic U937 cells through down regulation of ERK and Akt. Int Immunopharmacol
    21. (2000). HM: Radicicol suppresses expression of inducible nitric-oxide synthase by blocking p38 kinase and nuclear factor-kappaB/Rel in lipopolysaccharide-stimulated macrophages. J Pharmacol Exp Ther
    22. (2004). Hong JT: Antiarthritic effect of bee venom: inhibition of inflammation mediator generation by suppression of NF-kappaB through interaction with the p50 subunit. Arthritis Rheum
    23. (2006). Hong JT: Inhibitory effect of sesaminol glucosides on lipopolysaccharide-induced NF-kappaB activation and target gene expression in cultured rat astrocytes. Neurosci Res
    24. (2006). Hong JT: Melittin inhibits vascular smooth muscle cell proliferation through induction of apoptosis via suppression of nuclear factor-kappaB and Akt activation and enhancement of apoptotic protein expression. J Pharmacol Exp Ther
    25. (1998). IkappaB-NF-kappaB structures: at the interface of inflammation control. Cell
    26. (2002). Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase.
    27. (2007). Involvement of mitogen-activated protein kinases (MAPKs) during testicular ischemia-reperfusion injury in nuclear factor-kappaB knock-out mice. Life Sci
    28. (2005). JP: Inhibition of lipopolysaccharide-induced expression of inducible nitric oxide synthase by phenolic (3E)-4-(2-hydroxyphenyl)but-3-en-2-one in RAW 264.7 macrophages. Biochem Pharmacol
    29. (2000). Lipopolysaccharide activates distinct signaling pathways in intestinal epithelial cell lines expressing Toll-like receptors.
    30. (1987). Luthra HS:
    31. (1998). Mackman NJ: Role of IKK1 and IKK2 in lipopolysaccharide signaling in human monocytic cells.
    32. (2002). Minghetti L: Modulation of PGE(2) and TNFalpha by nitric oxide and LPS-activated RAW 264.7 cells. Cytokine
    33. (1993). Nitric oxide activates cyclooxygenase enzymes.
    34. (2001). Nitric oxide and inflammatory mediators in the perpetuation of osteoarthritis. Curr Rheumatol Rep
    35. (2001). Oettgen P: ESE-1 is a novel transcriptional mediator of inflammation that interacts with NFκB to regulate the inducible nitric-oxide synthase gene.
    36. Ohuchi K: Inhibition of lipopolysaccharide-induced expression of inducible nitric oxide synthase and tumor necrosis factor-αby 2'-hydroxychalcone derivatives
    37. (1998). Reduced progression of experimental osteoarthritis in vivo by selective inhibition of inducible nitric oxide synthase. Arthritis Rheum
    38. (1994). Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase.
    39. (1999). SA: Similarities and differences between human and murine TNF promoters in their response to lipopolysaccharide.
    40. (2006). Sautebin L: Inhibition of nitric oxide biosynthesis by anthocyanin fraction of blackberry extract. Nitric Oxide
    41. (1995). SE: The role of amphipathicity in the folding, self-association and biological activity of multiple subunit small proteins.
    42. (2002). Selective COX-2 inhibitors and dual acting anti-inflammatory drugs: critical remarks. Curr Med Chem
    43. (2006). Tanshinone IIA inhibits LPS-induced NF-kappaB activation
    44. (2003). Tidball JG: Expression of a muscle-specific, nitric oxide synthase transgene prevents muscle membrane injury and reduces muscle inflammation during modified muscle use in mice.
    45. (2004). TK: Triptolide inhibits murine-inducible nitric oxide synthase expression by down-regulating lipopolysaccharide-induced activity of nuclear factor-kappa B and c-Jun NH2-terminal kinase.
    46. (1999). Vellenga E: Extracellular-regulated kinase 1/2, Jun N-terminal kinase, and c-Jun are involved in NF-kappa Bdependent IL-6 expression in human monocytes.
    47. (1999). WW: Involvement of p38 mitogen-activated protein kinase

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.